Heron Therapeutics Analyst Ratings
Heron Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/25/2023 | 224.68% | Needham | $6 → $5 | Maintains | Buy |
| 05/12/2023 | 289.61% | Needham | $7 → $6 | Maintains | Buy |
| 04/21/2023 | 354.55% | Needham | → $7 | Reiterates | → Buy |
| 03/24/2023 | 549.35% | Evercore ISI Group | $15 → $10 | Maintains | Outperform |
| 03/24/2023 | 354.55% | Needham | $8 → $7 | Maintains | Buy |
| 11/09/2022 | 419.48% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 549.35% | Needham | $14 → $10 | Maintains | Buy |
| 05/10/2022 | 809.09% | Needham | $16 → $14 | Maintains | Buy |
| 12/02/2020 | 1458.44% | SVB Leerink | $21 → $24 | Maintains | Outperform |
| 05/27/2020 | 1458.44% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 03/02/2020 | 2757.14% | Needham | $48 → $44 | Maintains | Buy |
| 02/20/2020 | 3016.88% | Needham | $50 → $48 | Maintains | Buy |
| 10/03/2019 | 1977.92% | JMP Securities | $38 → $32 | Reiterates | → Market Outperform |
| 09/14/2018 | 3471.43% | Stifel | → $55 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/25/2023 | 224.68% | 尼德姆 | 6 美元 → 5 美元 | 維護 | 購買 |
| 05/12/2023 | 289.61% | 尼德姆 | 7 美元 → 6 美元 | 維護 | 購買 |
| 04/21/2023 | 354.55% | 尼德姆 | → 7 美元 | 重申 | → 購買 |
| 2023 年 3 月 24 日 | 549.35% | Evercore ISI 集團 | 15 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 2023 年 3 月 24 日 | 354.55% | 尼德姆 | 8 美元 → 7 美元 | 維護 | 購買 |
| 11/09/2022 | 419.48% | 尼德姆 | 10 美元 → 8 美元 | 維護 | 購買 |
| 06/30/2022 | 549.35% | 尼德姆 | 14 美元 → 10 美元 | 維護 | 購買 |
| 05/10/2022 | 809.09% | 尼德姆 | 16 美元 → 14 美元 | 維護 | 購買 |
| 12/02/2020 | 1458.44% | SVB Leerink | 21 美元 → 24 美元 | 維護 | 跑贏大盤 |
| 05/27/2020 | 1458.44% | 古根海姆 | → 24 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/02/2020 | 2757.14% | 尼德姆 | 48 美元 → 44 美元 | 維護 | 購買 |
| 02/20/2020 | 3016.88% | 尼德姆 | 50 美元 → 48 美元 | 維護 | 購買 |
| 2019 年 3 月 10 日 | 1977.92% | JMP 證券 | 38 美元 → 32 美元 | 重申 | → 市場跑贏大盤 |
| 09/14/2018 | 3471.43% | Stifel | → 55 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Heron Therapeutics (HRTX)?
Heron Therapeutics（HRTX）的目標價格是多少？
The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on July 25, 2023. The analyst firm set a price target for $5.00 expecting HRTX to rise to within 12 months (a possible 224.68% upside). 6 analyst firms have reported ratings in the last year.
Needham於2023年7月25日公佈了Heron Therapeutics（納斯達克股票代碼：HRTX）的最新目標股價。這家分析公司將目標股價定爲5.00美元，預計HRTX將在12個月內升至12個月內（可能上漲224.68％）。去年有6家分析公司公佈了評級。
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
分析師對Heron Therapeutics（HRTX）的最新評級是多少？
The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics maintained their buy rating.
Heron Therapeutics（納斯達克股票代碼：HRTX）的最新分析師評級由Needham提供，Heron Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
Heron Therapeutics（HRTX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on July 25, 2023 so you should expect the next rating to be made available sometime around July 25, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Heron Therapeutics的高管和客戶交談以及聽取財報電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Heron Therapeutics的最後一次評級是在2023年7月25日提交的，因此你應該預計下一個評級將在2024年7月25日左右公佈。
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
分析師對 Heron Therapeutics (HRTX) 的評級正確嗎？
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a maintained with a price target of $6.00 to $5.00. The current price Heron Therapeutics (HRTX) is trading at is $1.54, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Heron Therapeutics（HRTX）評級維持不變，目標股價爲6.00美元至5.00美元。Heron Therapeutics（HRTX）目前的交易價格爲1.54美元，超出了分析師的預測區間。